The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
The Demand for New Antibiotics: Antimicrobial Peptides, Nanoparticles, and Combinatorial Therapies as Future Strategies in Antibacterial Agent Design
Open accessAbstract
The inappropriate use of antibiotics and an inadequate control of infections have led to the emergence of resistant strains which represent a major threat to public health and the global economy. Therefore, research and development of a new generation of antimicrobials to mitigate the spread of antibiotic resistance has become imperative. Current research and technology developments have promoted the improvement of antimicrobial agents that can selectively interact with a target site (e.g., a gene or a cellular process) or a specific pathogen. Antimicrobial peptides and metal nanoparticles exemplify a novel approach to treat infectious diseases. Nonetheless, combinatorial treatments have been recently considered as an excellent platform to design and develop the next generation of antibacterial agents. The combination of different drugs offers many advantages over their use as individual chemical moieties; these include a reduction in dosage of the individual drugs, fewer side effects compared to the monotherapy, reduced risk for the development of drug resistance, a better combined response compared to the effect of the individual drugs (synergistic effects), wide-spectrum antibacterial action, and the ability to attack simultaneously multiple target sites, in many occasions leading to an increased antibacterial effect. The selection of the appropriate combinatorial treatment is critical for the successful treatment of infections. Therefore, the design of combinatorial treatments provides a pathway to develop antimicrobial therapeutics with broad-spectrum antibacterial action, bactericidal instead of bacteriostatic mechanisms of action, and better efficacy against multidrug-resistant bacteria.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449
The bactericidal effect of silver nanoparticles
Morones, J. R., Elechiguerra, J. L., Camacho, A., Holt, K., Kouri, J. B., Ramírez, J. T., & Yacaman, M. J. (2005) · Nanotechnology · doi:10.1088/0957-4484/16/10/059 · Cited by 6,668
The antimicrobial activity of nanoparticles: present situation and prospects for the future
Wang, L., Hu, C., & Shao, L. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s121956 · Cited by 4,062
Antimicrobial Peptides: An Emerging Category of Therapeutic Agents
Mahlapuu, M., Håkansson, J., Ringstad, L., & Björn, C. (2016) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2016.00194 · Cited by 1,927
Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review
Mulani, M. S., Kamble, E. E., Kumkar, S. N., Tawre, M. S., & Pardesi, K. R. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00539 · Cited by 1,644
Clinical relevance of the ESKAPE pathogens
Pendleton, J. N., Gorman, S. P., & Gilmore, B. F. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.13.12 · Cited by 1,423
A review of the biomaterials technologies for infection-resistant surfaces
Campoccia, D., Montanaro, L., & Arciola, C. R. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.07.089 · Cited by 1,358
Shahverdi, A. R., Fakhimi, A., Shahverdi, H. R., & Minaian, S. (2007) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2007.02.001 · Cited by 1,299
Krause, K. M., Serio, A. W., Kane, T. R., & Connolly, L. E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a027029 · Cited by 1,149
The antimicrobial peptides and their potential clinical applications.
Lei, J., Sun, L., Huang, S., Zhu, C., Li, P., He, J., Mackey, V., Coy, D. H., & He, Q. (2019) · PubMed · Cited by 1,116
Cited by
Antimicrobial Peptides—Mechanisms of Action, Antimicrobial Effects and Clinical Applications
Talapko, J., Meštrović, T., Juzbašić, M., Tomas, M., Erić, S., Horvat Aleksijević, L., Bekić, S., Schwarz, D., Matić, S., Neuberg, M., et al. (2022) · Antibiotics · doi:10.3390/antibiotics11101417 · Cited by 281
Self-Assembly Pathways and Antimicrobial Properties of Lysozyme in Different Aggregation States
Kummer, N., Wu, T., De France, K. J., Zuber, F., Ren, Q., Fischer, P., Campioni, S., & Nyström, G. (2021) · Biomacromolecules · doi:10.1021/acs.biomac.1c00870 · Cited by 46
Metadata
- Authors
- León-Buitimea, A., Garza-Cárdenas, C. R., Garza-Cervantes, J. A., Lerma-Escalera, J. A., & Morones-Ramírez, J. R.
- Venue
- Frontiers in Microbiology
- Publisher
- Frontiers Media SA
- Published
- 2020-07-24
- Volume
- 11
- Pages
- 1669-1669
- ISSN
- 1664-302X (ISSN-L)
- OpenAlex
- W3045445502
- Cited by
- 274
- References
- 84
- FWCI
- 23.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Demand for New Antibiotics: Antimicrobial Peptides, Nanoparticles, and Combinatorial Therapies as Future Strategies in Antibacterial Agent Design. https://app.cochat.ai/papers/10.3389/fmicb.2020.01669
- The paper
- León-Buitimea, A., Garza-Cárdenas, C. R., Garza-Cervantes, J. A., Lerma-Escalera, J. A., & Morones-Ramírez, J. R. (2020). The Demand for New Antibiotics: Antimicrobial Peptides, Nanoparticles, and Combinatorial Therapies as Future Strategies in Antibacterial Agent Design. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2020.01669
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.